STOK - Company ID 0001623526
The table below shows Stoke Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$60.58M | $131.83M | -$24.57M | -$21.36M | $32.49M | -$20.14M |
| Capital expenditure | $353.00K | $152.00K | $12.00K | $165.00K | $841.00K | $204.00K |
| Investing cash flow | $50.69M | $13.63M | $9.99M | $53.09M | -$135.78M | -$204.00K |
| Dividends paid | - | - | - | - |
Stoke Therapeutics, Inc. reported operating cash flow of $45.59M for fiscal year 2025. That is up 152.5% from -$86.85M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow grew from -$10.96M (FY 2018) to $45.59M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $84.33M | $1.37M | $1.72M | $45.05M | $42.51M | $546.00K |